Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | RORC | P51449 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31677853 | 0.92 | KDM4E (0.42) | KMT2AKDM4ESMN1; SMN2MAPTRORC | |
| SCHEMBL31678788 | 0.90 | KDM4E (0.41) | KMT2AKDM4ESMN1; SMN2MAPTRORC | |
| SCHEMBL31677868 | 0.83 | RORC (0.40) | KMT2AKDM4EMAPTRORCMEN1 | |
| SCHEMBL31677686 | 0.82 | RORC (0.39) | KMT2AKDM4ESMN1; SMN2MAPTRORC | |
| SCHEMBL31678860 | 0.82 | RORC (0.39) | KMT2AKDM4ESMN1; SMN2MAPTRORC | |
| SCHEMBL31653824 | 0.82 | KDM4E (0.46) | KMT2AKDM4ESMN1; SMN2MAPTRORC | |
| SCHEMBL31653762 | 0.81 | KDM4E (0.42) | KMT2AKDM4ESMN1; SMN2MAPTRORC | |
| SCHEMBL31678840 | 0.81 | RORC (0.39) | KMT2AKDM4EMAPTRORCMEN1 | |
| SCHEMBL31677653 | 0.81 | MAPK3 (0.40) | KMT2ASMN1; SMN2MAPTRORCMEN1 | |
| SCHEMBL31678000 | 0.80 | KMT2A (0.36) | KMT2AKDM4ESMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2025-08-28 | — | — | US | claimed |
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | WRN, RECQL, BLM | KMT2A 1697/4885KDM4E 2390/4885SMN1; SMN2 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.